Skip to main content
BIO
NYSE Industrial Applications And Services

Stockholders Approve Amended Incentive Plan, Authorizing 335,000 Additional Shares

Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
8
Price
$287.84
Mkt Cap
$7.762B
52W Low
$211.43
52W High
$343.12
Market data snapshot near publication time

Summary

Bio-Rad Laboratories' stockholders approved an amended incentive plan, authorizing an additional 335,000 shares for issuance and extending the plan's duration, while also rejecting a proposal to change the dual-class capital structure.


Key Events

  • Incentive Plan Share Pool Increased

    Stockholders approved the Amended 2017 Incentive Award Plan, increasing the shares reserved for issuance by 335,000 shares and extending the plan's expiration date to March 18, 2036. This provides a larger pool for future equity compensation but represents potential dilution.

  • Dual-Class Capital Structure Maintained

    A stockholder proposal to change the company's dual-class capital structure was not approved, meaning the current structure will remain in place.

  • Routine Annual Meeting Approvals

    Shareholders elected all nominated directors, ratified KPMG LLP as independent auditors, and approved executive compensation in a non-binding advisory vote.


Analysis

Stockholders approved an amendment to the 2017 Incentive Award Plan, which significantly increases the pool of shares available for future grants to employees and directors. This authorization of 335,000 additional shares represents a notable potential dilution for existing shareholders, even though it is intended for compensation and retention. The extension of the plan's expiration date provides long-term flexibility for the company's compensation strategy. Additionally, shareholders voted against a proposal to alter the dual-class capital structure, indicating a preference to maintain the current governance framework.

At the time of this filing, BIO was trading at $287.84 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $211.43 to $343.12. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIO - Latest Insights

BIO
May 17, 2026, 8:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $247.53
Real-time Price: $285.94 info
Change: +$38.41 (+16%) info
Market Cap: $7.698B info
BIO
Apr 30, 2026, 4:31 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $280.12
Real-time Price: $285.94 info
Change: +$5.82 (+2%) info
Market Cap: $7.698B info
BIO
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $287.84
Real-time Price: $285.94 info
Change: -$1.90 (-0.66%) info
Market Cap: $7.698B info
BIO
Mar 25, 2026, 4:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $273.60
Real-time Price: $285.94 info
Change: +$12.34 (+5%) info
Market Cap: $7.698B info
BIO
Feb 19, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $271.90
Real-time Price: $285.94 info
Change: +$14.04 (+5%) info
Market Cap: $7.698B info
BIO
Feb 12, 2026, 9:50 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $255.00
Real-time Price: $285.94 info
Change: +$30.94 (+12%) info
Market Cap: $7.698B info
BIO
Feb 12, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $292.42
Real-time Price: $285.94 info
Change: -$6.48 (-2%) info
Market Cap: $7.698B info